慢乙肝和慢重肝患者趋化因子的表达差异及干扰素治疗后的变化

发布时间：2018-05-02 16:06

本文选题：HBV感染 + CXCL　；参考：《现代预防医学》2017年05期

【摘要】：目的探讨外周血趋化因子CCL20、CXCL9及CXCL11在HBV慢性感染后不同临床分型间的表达差异以及干扰素治疗对慢乙肝患者外周血中这些趋化因子水平的影响。方法采用酶联免疫吸附分析(enzyme linked immunosorbent assay ELISA)检测外周血趋化因子CCL20、CXCL9及CXCL11在慢乙肝组、慢重肝组和健康对照组之间的差异;对30例慢乙肝患者用干扰素治疗,于治疗后第4周、第12周、第24周和第48周,采集外周血,检测上述趋化因子的水平,以及ALT、HBV-DNA和HBs Ag的变化。结果慢乙肝组、慢重肝组和对照组间外周血趋化因子CCL20、CXCL9、CXCL11水平差异有统计学意义(F分别为3.802、2.573、2.809;P分别为0.024、0.037、0.043),且慢重肝组高于慢乙肝组,慢乙肝组高于对照组;经干扰素治疗12周、24周和48周后的慢乙肝患者,其外周血趋化因子CCL20、CXCL9及CXCL11的表达也降低(P0.05),同时发现ALT、HBV-DNA以及HBs Ag均有明显下降。结论趋化因子CCL20、CXCL9及CXCL11在HBV慢性感染的不同临床分型间存在差异,干扰素治疗可以降低慢乙肝患者的炎症反应和HBV病毒水平。
[Abstract]:Objective to investigate the expression of CXCL9 and CXCL11 in peripheral blood of patients with chronic hepatitis B (CHB) and the effect of interferon treatment on the levels of these chemokines in patients with chronic hepatitis B (CHB). Methods Enzyme-linked immunosorbent assay (linked immunosorbent assay ELISA) was used to detect the difference of peripheral blood chemokine CCL20CXCL9 and CXCL11 between chronic hepatitis B group, chronic heavy liver group and healthy control group, and 30 patients with chronic hepatitis B were treated with interferon at the 4th week after treatment. Peripheral blood samples were collected at week 12, week 24 and week 48. The levels of these chemokines and the changes of HBV-DNA and HBs Ag in alt were detected. Results the levels of CXCL11 in peripheral blood of chronic hepatitis B group, slow and heavy liver group and control group were significantly higher than those of chronic hepatitis B group and chronic hepatitis B group. The levels of CXCL11 in peripheral blood of chronic hepatitis B group were significantly higher than those of chronic hepatitis B group and chronic hepatitis B group (P = 3.802, 2.573, 2.809, P = 0.024, 0.037, 0.043, respectively), while that of chronic hepatitis B group was higher than that of chronic hepatitis B group, and that of chronic hepatitis B group was higher. The expression of CCL20CXCL9 and CXCL11 in peripheral blood of patients with chronic hepatitis B after 12 weeks and 48 weeks of interferon treatment also decreased P0.05, and it was found that both ALTV-DNA and HBs Ag were significantly decreased. Conclusion the chemokine CCL20CXCL9 and CXCL11 are different in different clinical types of chronic HBV infection. Interferon treatment can reduce the inflammatory response and HBV virus level in patients with chronic hepatitis B.
【作者单位】：四川大学华西公共卫生学院(华西第四医院);成都市公共卫生临床医疗中心;
【分类号】：R512.6

【参考文献】